Transcription factor EB, a promising therapeutic target in cardiovascular disease

PeerJ. 2024 Oct 11:12:e18209. doi: 10.7717/peerj.18209. eCollection 2024.

Abstract

Cardiovascular disease (CVD) remains the major cause of morbidity and mortality around the world. Transcription factor EB (TFEB) is a master regulator of lysosome biogenesis and autophagy. Emerging studies revealed that TFEB also mediates cellular adaptation responses to various stimuli, such as mitochondrial dysfunction, pathogen infection and metabolic toxin. Based on its significant capability to modulate the autophagy-lysosome process (ALP), TFEB plays a critical role in the development of CVD. In this review, we briefly summarize that TFEB regulates cardiac dysfunction mainly through ameliorating lysosomal and mitochondrial dysfunction and reducing inflammation.

Keywords: Autophagic flux; Cardiovascular disease; Lysosome; TFEB.

Publication types

  • Review

MeSH terms

  • Animals
  • Autophagy* / drug effects
  • Basic Helix-Loop-Helix Leucine Zipper Transcription Factors* / genetics
  • Basic Helix-Loop-Helix Leucine Zipper Transcription Factors* / metabolism
  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / metabolism
  • Humans
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Lysosomes* / metabolism
  • Mitochondria / drug effects
  • Mitochondria / metabolism

Substances

  • Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
  • TFEB protein, human